Cannabis and Chemotherapy-Induced Nausea and Vomiting

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Not medical advice

This article is not medical advice. It summarizes published evidence for educational purposes only. Chemotherapy regimens vary enormously in emetogenicity, and antiemetic choices depend on your specific drugs, liver function, renal function, other medications, and cancer type. Do not add, substitute, or stop any antiemetic without talking to your oncologist or oncology pharmacist. Stopping a prescribed antiemetic to use cannabis instead is dangerous without medical supervision.

Plain-language summary

Chemotherapy can cause severe nausea and vomiting (CINV). Two prescription drugs containing synthetic THC — dronabinol (Marinol, Syndros) and nabilone Cesamet — are FDA-approved for CINV in patients who haven't responded to standard antiemetics Strong evidence^[1][2][3].

When tested in the 1970s–80s, these drugs outperformed the antiemetics then available (like prochlorperazine) Strong evidence^[4][5]. However, modern first-line regimens—combining 5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant), and dexamethasone—are now more effective and are the standard of care Strong evidence^[6][7]. Cannabinoids are recommended as an option for breakthrough or refractory CINV by major oncology organizations (ASCO, NCCN), not as first-line therapy.

Evidence for smoked or vaporized cannabis flower treating CINV is much weaker than for the pills—most data is observational or extrapolated from animal studies Weak / limited^[9].

What probably works

Oral synthetic THC (dronabinol, nabilone) for chemotherapy-induced nausea Strong evidence. A 2015 Cochrane systematic review of 23 randomized controlled trials found cannabinoids were more effective than placebo at controlling CINV ^[4]. A 2001 BMJ systematic review of earlier trials reached similar conclusions ^[5]. When these drugs were directly compared to antiemetics available at the time (prochlorperazine, metoclopramide, haloperidol), cannabinoids performed comparably or better, and patients often preferred them Strong evidence^[4][5].

These drugs are approved specifically for patients whose nausea is not controlled by standard antiemetics—i.e., breakthrough or refractory CINV. The mechanism is biologically plausible: CB1 receptors in the brainstem dorsal vagal complex modulate vomiting signals, and CB1 agonists show antiemetic activity in preclinical models Strong evidence^[10].

Cannabinoids as add-on therapy for refractory CINV Weak / limited. The CAMP-1 trial and smaller studies suggest that adding an oral THC:CBD product (nabiximols) to standard antiemetics may improve control of refractory delayed nausea, though effect sizes are modest ^[8]. Common side effects—sedation, dizziness, dysphoria—limit tolerability, and completion rates are variable.

Dose, formulation, and THC:CBD ratio all matter: oral dronabinol and nabilone come in fixed doses, whereas cannabis products vary widely and cannot be standardized reliably Strong evidence^[1][2][3].

What might work

Smoked or vaporized cannabis flower for CINV Weak / limited. Small, older trials of smoked cannabis for CINV exist, but they tested cannabis with much lower THC content than today's products and rarely compared against modern antiemetics ^[9]. Current evidence rests mainly on patient surveys and observational studies reporting that people use cannabis and perceive benefit—suggestive but not proof of efficacy in controlled settings Weak / limited^[9].

CBD alone for nausea Weak / limited. Preclinical work suggests CBD has antiemetic activity via 5-HT1A receptors ^[10], but high-quality human trials of CBD monotherapy in CINV are essentially absent. Marketing claims about CBD for nausea vastly outpace the clinical data.

Cannabis for anticipatory nausea (the conditioned nausea that develops before chemotherapy sessions) Weak / limited. Preclinical models suggest cannabinoids may reduce anticipatory responses ^[10], but human trials are sparse and standard treatment is behavioral therapy plus short-acting benzodiazepines.

What doesn't work or has weak evidence

• Cannabis as a stand-alone replacement for modern triple-therapy regimens (5-HT3 antagonist + NK1 antagonist + dexamethasone) in highly emetogenic chemotherapy No data. No randomized trial has shown cannabinoids match or exceed this combination.

• Topical cannabis products for nausea No data. There is no plausible pharmacokinetic basis for cannabinoids absorbed through skin to reach brainstem vomiting centers in effective concentrations, and no trial evidence exists.

• Choosing 'indica' vs. 'sativa' strains for antiemetic effect No data. The indica/sativa distinction does not reliably predict cannabinoid or terpene composition, and no clinical trial supports either category for CINV. This is dispensary marketing folklore.

• Specific terpene profiles (myrcene, limonene, pinene, etc.) selected for antiemetic action No data. Some terpenes show biological activity in preclinical models, but no human CINV trial has tested terpene-enriched products or validated a terpene profile for nausea control.

• Cannabis for highly emetogenic regimens in patients who tolerate standard antiemetics No data. No evidence supports cannabis as first-line for these patients.

What we don't know

• Head-to-head efficacy of inhaled cannabis vs. oral THC pills in modern CINV regimens. Almost no randomized trials exist comparing these routes directly.

• Optimal THC:CBD ratios for CINV management vs. side-effect burden. Most trials use fixed-dose pharmaceutical products; the question of whether 1:1, 2:1, or THC-dominant products perform differently is essentially unexamined in human CINV trials.

• Detailed pharmacokinetic interactions between cannabis and specific chemotherapy agents. Some chemotherapy drugs (e.g., certain tyrosine kinase inhibitors) are metabolized through CYP3A4 and CYP2C9, which THC and CBD inhibit; clinical consequences are not well mapped Weak / limited^[11].

• Long-term effects of cannabis use during chemotherapy on treatment outcomes (tumor response, survival, recurrence). Retrospective signals exist around cannabis potentially impairing response to checkpoint-inhibitor immunotherapy, but data are sparse and preliminary Weak / limited^[12]. This warrants open discussion with your oncology team, especially if you are on immunotherapy.

• Pediatric efficacy and safety. Nabilone has some pediatric data; smoked or vaporized cannabis in pediatric oncology is essentially unstudied.

Comparison with standard treatments

Modern CINV prophylaxis for highly emetogenic chemotherapy (e.g., cisplatin, AC regimens) typically combines Strong evidence^[6][7]:

1. A 5-HT3 receptor antagonist (ondansetron, palonosetron)
2. An NK1 receptor antagonist (aprepitant, fosaprepitant, rolapitant)
3. Dexamethasone (a corticosteroid)
4. Sometimes olanzapine (an atypical antipsychotic)

This four-drug or three-drug combination achieves complete response (no vomiting, no rescue medication) in approximately 70–80% of patients in modern trials Strong evidence^[6][7]. Cannabinoids have never been shown to match or exceed this regimen.

Cannabinoids are typically added when this standard regimen fails—i.e., for breakthrough or refractory CINV. ASCO and NCCN list dronabinol or nabilone as reasonable second-line options alongside olanzapine, lorazepam, or metoclopramide Strong evidence^[6][7].

For patients with mild to moderately emetogenic regimens, or those who cannot tolerate standard antiemetics due to contraindications or side effects, cannabinoids may have a relatively larger role. However, they remain not first-line.

Risks and side effects

Common cannabinoid side effects in CINV trials Strong evidence^[4][5]:

• Sedation and dizziness (very frequent)
• Dry mouth
• Dysphoria, anxiety, paranoia—particularly in older patients and those not accustomed to cannabis
• Orthostatic hypotension
• Tachycardia
• Cognitive impairment

In older trials, dropout rates due to side effects were notable; some patients found the psychoactive effects worse than the underlying nausea. Nabilone and dronabinol are more predictable than inhaled cannabis because dose is fixed and bioavailability is standardized Strong evidence^[2][3].

Other important safety considerations:

• Drug interactions: THC and CBD inhibit several CYP450 enzymes (particularly CYP3A4 and CYP2C9); this can affect blood levels of some chemotherapy agents, anticoagulants (warfarin), immunosuppressants (tacrolimus), and other drugs Weak / limited^[11]. Discuss with your pharmacist if you are taking multiple medications.

• Smoking risk during neutropenia: combustion of plant material produces particulates and can carry fungal and bacterial contamination. Vaporization or oral routes are safer during periods of low white blood cell count Weak / limited^[1].

• Cannabis hyperemesis syndrome (CHS): Paradoxically, chronic heavy cannabis use can cause cyclic nausea and vomiting that may worsen or persist during chemotherapy. See Cannabis and Nausea for more details Strong evidence.

• Potential immunotherapy interaction: Preliminary data suggest cannabis use may blunt response to checkpoint-inhibitor immunotherapy (anti-PD-1/PD-L1 agents) Weak / limited^[12]. This is not settled, but it is a reason to disclose cannabis use openly to your oncology team, especially if you are receiving immunotherapy.

• Impaired judgment and motor function: Cannabinoids can impair cognitive function and coordination, which matters during active treatment when you may need to manage appointments, medications, and clinical decisions.

Practical considerations and next steps

If you are experiencing breakthrough or refractory CINV despite standard antiemetics:

1. Talk to your oncologist or oncology pharmacist first. Describe what you've already tried, what worked, and what side effects you are experiencing. They can assess whether dronabinol, nabilone, or Cesamet is appropriate for your situation and check for drug interactions.

1. If prescribed a synthetic THC drug, use it regularly as directed during your chemotherapy cycle, not just when nausea starts. Most evidence is from scheduled dosing, not as-needed use.

1. Start low and titrate slowly if this is your first time with cannabis or cannabinoids. Older adults and cannabis-naïve patients are more susceptible to dizziness, dysphoria, and orthostatic effects.

1. Avoid smoking during chemotherapy, particularly if your white blood cell count is low (neutropenia). Vaporization or oral forms are safer.

1. Monitor for cannabis hyperemesis. If you develop a cyclic pattern of worsening nausea or new vomiting despite treatment, tell your team—this may warrant stopping cannabis rather than adding more.

1. Disclose all cannabis use to your team, especially if you are on immunotherapy or taking multiple medications. Cannabinoids interact with several drug-metabolizing enzymes.

1. Keep an eye on emerging data. If you are on a checkpoint inhibitor (like pembrolizumab or nivolumab) and using cannabis, ask your team if new safety data have emerged since your last visit.

Sources

How this page was made

Related

• Cannabis and Chemotherapy Side Effects — Evidence for cannabis in managing chemotherapy side effects, with honest assessment of ris...
• Cannabis and Hospice Care — Evidence summary for cannabis use in end-of-life symptom management and its role alongside...
• Cannabis and Nausea — Cannabinoids reduce chemotherapy nausea; evidence is weak for other causes.
• Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
• Cannabis-Induced Anxiety — How THC dose, individual vulnerability, and setting trigger acute anxiety; what actually h...
• Cesamet (Nabilone) — Synthetic THC approved for refractory chemotherapy nausea; off-label use varies in evidenc...